Straits Times Index
3,384.29 +20.61 (+0.61%) Nikkei
27,509.46 +107.41 (+0.39%) Hang Seng
21,660.47 -297.89 (-1.36%) FTSE 100
7,901.80 +81.64 (+1.04%) BTC-USD
23,423.02 +13.95 (+0.06%) CMC Crypto 200
535.42 -1.43 (-0.27%)
ABBV Jan 2025 175.000 put
| Previous close | 27.50 |
| Open | 27.50 |
| Bid | 32.95 |
| Ask | 35.40 |
| Strike | 175.00 |
| Expiry date | 2025-01-17 |
| Day's range | 27.50 - 27.50 |
| Contract range | N/A |
| Volume | |
| Open interest | 11 |
- Motley Fool
2 Stocks Down More Than 6% to Buy Right Now
In fact, two stocks that outperformed the S&P 500 last year are now down more than 6% since the start of the year: Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV).. Motley Fool contributors Adria Cimino and Keith Speights talk about why these two stocks actually make great buys right now. Adria Cimino (Johnson & Johnson): J&J may have disappointed investors when it reported fourth-quarter earnings on Jan. 24.
- Motley Fool
3 Unstoppable Dividend Stocks to Buy in February
Any time is a good time to buy solid dividend stocks. Here's why they chose Abbott Laboratories (NYSE: ABT), AbbVie (NYSE: ABBV), and Johnson & Johnson (NYSE: JNJ). David Jagielski (Abbott Laboratories): One dividend stock that should be attractive to long-term investors is Abbott Laboratories.
- Zacks
AbbVie Q4 Preview: What's in Store?
AbbVie has put in a mixed earnings performance, exceeding bottom line estimates in five consecutive quarters but falling short of sales expectations in each instance.
